This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koh, Y.
Right arrow Articles by Mitsuya, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koh, Y.
Right arrow Articles by Mitsuya, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2009, p. 997-1006, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.00689-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

GRL-02031, a Novel Nonpeptidic Protease Inhibitor (PI) Containing a Stereochemically Defined Fused Cyclopentanyltetrahydrofuran Potent against Multi-PI-Resistant Human Immunodeficiency Virus Type 1 In Vitro{triangledown}

Yasuhiro Koh,1 Debananda Das,2 Sofiya Leschenko,3 Hirotomo Nakata,1,2 Hiromi Ogata-Aoki,1 Masayuki Amano,1 Maki Nakayama,1 Arun K. Ghosh,3 and Hiroaki Mitsuya1,2*

Departments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Kumamoto 860-8556, Japan,1 Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892,2 Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, Indiana 479073

Received 27 May 2008/ Returned for modification 8 August 2008/ Accepted 16 October 2008

We generated a novel nonpeptidic protease inhibitor (PI), GRL-02031, by incorporating a stereochemically defined fused cyclopentanyltetrahydrofuran (Cp-THF) which exerted potent activity against a wide spectrum of human immunodeficiency virus type 1 (HIV-1) isolates, including multidrug-resistant HIV-1 variants. GRL-02031 was highly potent against laboratory HIV-1 strains and primary clinical isolates, including subtypes A, B, C, and E (50% effective concentration [EC50] range, 0.015 to 0.038 µM), with minimal cytotoxicity (50% cytotoxic concentration, >100 µM in CD4+ MT-2 cells), although it was less active against two HIV-2 strains (HIV-2EHO and HIV-2ROD) (EC50, ~0.60 µM) than against HIV-1 strains. GRL-02031 at relatively low concentrations blocked the infection and replication of each of the HIV-1NL4-3 variants exposed to and selected by up to 5 µM of saquinavir, amprenavir, indinavir, nelfinavir, or ritonavir and 1 µM of lopinavir or atazanavir (EC50 range, 0.036 to 0.14 µM). GRL-02031 was also potent against multi-PI-resistant clinical HIV-1 variants isolated from patients who had no response to the conventional antiretroviral regimens that then existed, with EC50s ranging from 0.014 to 0.042 µM (changes in the EC50s were less than twofold the EC50 for wild-type HIV-1). Upon selection of HIV-1NL4-3 in the presence of GRL-02031, mutants carrying L10F, L33F, M46I, I47V, Q58E, V82I, I84V, and I85V in the protease-encoding region and G62R (within p17), L363M (p24-p2 cleavage site), R409K (within p7), and I437T (p7-p1 cleavage site) in the gag-encoding region emerged. GRL-02031 was potent against a variety of HIV-1NL4-3-based molecular infectious clones containing a single primary mutation reported previously or a combination of such mutations, although it was slightly less active against HIV-1 variants containing consecutive amino acid substitutions: M46I and I47V or I84V and I85V. Structural modeling analysis demonstrated a distinct bimodal binding of GRL-02031 to protease, which may provide advantages to GRL-02031 in blocking the replication of a wide spectrum of HIV-1 variants resistant to PIs and in delaying the development of resistance of HIV-1 to GRL-02031. The present data warrant the further development of GRL-02031 as a potential therapeutic agent for the treatment of infections with primary and multidrug-resistant HIV-1 variants.

* Corresponding author. Mailing address: Department of Hematology, Kumamoto University Graduate School of Medicine, 1-1-1 Honjo, Kumamoto 860-8556, Japan. Phone: (81) 96-373-5156. Fax: (81) 96-363-5265. E-mail: hmitsuya{at}helix.nih.gov

{triangledown} Published ahead of print on 27 October 2008.

Antimicrobial Agents and Chemotherapy, March 2009, p. 997-1006, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.00689-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»